NOVEL METHODS
Provided is a method of treating female sexual dysfunction comprising administering a therapeutically effective amount of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, substantially free of the corresponding (−) enantiomer, to a female in need thereof.
1 . A method of prophylaxis or treatment of female sexual dysfunction in a female in need thereof comprising administering a therapeutically effective amount of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, to the female.
2 - 6 . (canceled)
7 . The method of claim 1 , wherein (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in pharmaceutically acceptable salt form is an acid addition salt.
8 . The method of claim 7 , wherein (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in pharmaceutically acceptable salt form is (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane hydrochloride.
9 . The method of claim 1 , wherein (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in pharmaceutically acceptable salt form is crystalline.
10 . The method of claim 8 , wherein (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane hydrochloride is Polymorph A.
11 - 14 . (canceled)
15 . The method of claim 1 comprising administering 25 mg to 600 mg of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form.
16 . The method of claim 15 comprising administering 100 mg to 600 mg of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form.
17 . The method of claim 16 comprising administering 100 mg to 200 mg of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form.
18 - 22 . (canceled)
23 . The method of claim 1 comprising administering (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, 24 hours or less before sexual activity.
24 . The method of claim 1 , wherein (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, is administered concurrently or sequentially, in either order, with another treatment for female sexual dysfunction.
25 . The method of claim 1 , wherein (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, is administered concurrently or sequentially, in either order, with a hormone or a derivative thereof, a prostaglandin, a melanocortin agonist, a phosphodiesterase inhibitor, a dopamine-norepinephrine reuptake inhibitor, a 5-hydroxytryptamine 1a receptor agonist, a dopamine agonist, a serotonin antagonist and reuptake inhibitor, a lubricant, vitamin E, mineral oil, or a combination thereof.
26 . The method of claim 1 , wherein the female has major depressive disorder.
27 . The method of claim 1 , wherein the female is taking an anti-hypertensive, an anticholinergic, a barbiturate, a benzodiazepine, an anti-depressant, a chemotherapeutic, or an opiate.
28 . The method of claim 27 , wherein the female is taking an anti-depressant.
29 . The method of claim 1 , wherein the sexual dysfunction is a side effect of a drug.
30 . The method of claim 1 , wherein the sexual dysfunction is a side effect of an anti-depressant.
31 . The method of claim 1 comprising administering a subthreshold amount of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, wherein the subthreshold amount is a subthreshold amount of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, for treatment of depression.
32 - 46 . (canceled)